<DOC>
	<DOCNO>NCT01719588</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness prolong release tapentadol hydrochloride relief moderate severe chronic non-cancer pain among Filipino patient .</brief_summary>
	<brief_title>A Safety Effectiveness Study Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate Severe Chronic Non-Cancer Pain</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( study conduct multiple site ) , observational study ( study investigators/ physician observe patient measure outcome ) . The study enroll approximately 100 patient take prolonged release tapentadol hydrochloride dose regimen stipulate product insert . As observational study , assessment patient base accepted clinical practice Philippines . Patients monitor baseline ( Day 1 ) throughout 84-day treatment period prolong release tapentadol hydrochloride ( every 7 day first two week , thereafter every 28 day next three month ) effectiveness help short form Brief Pain Inventory ( BPI ) questionnaire . Safety evaluation include assessment adverse event , clinical laboratory test , co-morbid condition . The total study conduct 3 year duration treatment 84 day .</detailed_description>
	<criteria>Filipino patient moderate severe noncancer pain onset 12 week less baseline visit pain require Schedule 2 opioid treatment per assessment prescribe physician Patients able independently communicate pain characteristic , understand complete self administer questionnaire Medically stable basis routine physical examination , medical history , vital sign time baseline visit Refuse protocoldefined use effective contraception Pregnant lactate woman Patients severe renal hepatic impairment , significant respiratory depression , acute severe bronchial asthma hypercapnia , suspect paralytic ileus Patients acute intoxication alcohol , hypnotic , centrally act analgesic , psychotropic drug receive muopioid receptor agonist analgesic , general anesthetic , phenothiazine , tranquilizer , sedatives Patients receive Monoamine oxidase ( MAO ) inhibitor take within last 14 day Patients documented history increase intracranial pressure , impaired consciousness , coma seizure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Moderate severe chronic non-cancer pain</keyword>
	<keyword>Prolonged release tapentadol hydrochloride</keyword>
	<keyword>Tapentadol PR</keyword>
	<keyword>Extended release tapentadol hydrochloride</keyword>
	<keyword>Nucynta PR</keyword>
</DOC>